InspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventi...
January 26 2021 - 5:30AM
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™
Embolic Prevention System (EPS) for the prevention of the stroke
caused by carotid artery disease, announced today multiple
presentations regarding CGuard EPS, including a live demonstration,
during the Leipzig Interventional Congress being held virtually
from January 25-29, 2021.
Highlights include:
Wednesday, January 27, 2021, “Innovative Concepts in
Carotid Revascularization”
- “12-month results from a prospective
real world multicenter clinical practice of CAD using the CGuard
Embolic Prevention system: the IRONGUARD 2 study.”
Author: Pasqualino Sirignano, M.D., Vascular and Endovascular
Surgery Division, Department of Surgery “Paride Stefanini,”
Policlinico Umberto I “Sapienza,” University of Rome.
- “Carotid artery revascularization: a
systematic review and meta-analysis comparing clinical outcomes of
second vs. first generation stents and CEA.” Author: Dr. Adam
Mazurek, Department of Cardiac & Vascular Diseases, John Paul
II Hospital, Jagiellonian University, Medical College, Krakow,
Poland; on behalf
of CARMEN Collaborators (CArotid
Revascularization systematic review and MEta-aNalysis).
Friday, January 29, 2021, “Innovative Concepts in
Peripheral Interventions”
- “CGuard EPS Live Case
Transmission from Leipzig,” a live demonstration of CGuard
implantation”
- “Combining TCAR reversed flow with mesh covered carotid stents:
can the outcome be as good as open surgery?” Author: Prof. Ralf
Kolvenbach, Head of the Cardiovascular Diseases Department, and
Medical Director of the Catholic Hospitals, Düsseldorf,
Germany
- “CGuard MicroNet covered stent:
clinical evidence.” Author: Prof. Piotr Musiałek - Department of
Cardiac and Vascular Diseases, Jagiellonian University, John Paul
II Hospital, Krakow, Poland.
“Our body of evidence that demonstrates the advantages of CGuard
over first-generation stents continues to grow through
presentations such as the ones being offered at this very
prestigious conference,” said Marvin Slosman, InspireMD’s President
and CEO. “We continue to collaborate with the many practitioners
who are excited about CGuard for their patients and to widen the
awareness of the product throughout the world in order to optimize
CAD treatment.”
About the CGuard® EPS
The CGuard® Embolic Protection System is an advanced platform
solution designed to deliver the flexibility of the traditional
open-cell stent with advanced protection from peri-procedural and
post-procedural embolic events caused by plaque prolapse through
the stent strut that can lead to stroke. CGuard’s unique MicroNet®
technology mitigates the prolapse and associated embolization and
has shown superior clinical outcomes for patients against
alternative carotid stent types, conventional and next-generation
double-layer stents, as well as invasive procedures such as
endarterectomy, a major surgical procedure. InspireMD’s
CGuard™ has created a new dimension in the protected treatment of
carotid artery disease and has the potential to establish a new
standard of care for the management of carotid artery disease and
stroke prevention.
About InspireMD, Inc.InspireMD seeks to utilize
its proprietary MicroNet® technology to make its products the
industry standard for carotid stenting by providing outstanding
acute results and durable, stroke-free, long-term outcomes. For
more information,
visit www.inspiremd.com. InspireMD routinely posts
information that may be important to investors in the Investors
section of its website.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) market acceptance of our existing and new
products, (ii) negative clinical trial results or lengthy product
delays in key markets, (iii) an inability to secure regulatory
approvals for the sale of our products, (iv) the impact of the
COVID-19 pandemic on our manufacturing, sales, business plan and
the global economy, (v) intense competition in the medical device
industry from much larger, multinational companies, (vi) product
liability claims, (vii) product malfunctions, (viii) our limited
manufacturing capabilities and reliance on subcontractors for
assistance, (ix) insufficient or inadequate reimbursement by
governmental and other third party payers for our products, (x) our
efforts to successfully obtain and maintain intellectual property
protection covering our products, which may not be successful, (xi)
legislative or regulatory reform of the healthcare system in both
the U.S. and foreign jurisdictions, (xii) our reliance on single
suppliers for certain product components, (xiii) the fact that we
will need to raise additional capital to meet our business
requirements in the future and that such capital raising may be
costly, dilutive or difficult to obtain and (xiv) the fact that we
conduct business in multiple foreign jurisdictions, exposing us to
foreign currency exchange rate fluctuations, logistical and
communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each
jurisdiction. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Investor Contacts:
Craig ShoreChief Financial OfficerInspireMD,
Inc.888-776-6804craigs@inspiremd.com
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Apr 2024 to May 2024
InspireMD (AMEX:NSPR)
Historical Stock Chart
From May 2023 to May 2024